Jessica Mattison, APRN
Adult Health · Lincoln, NENPI 1467011445
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,944 of the $2,317 with a category attached, or 83.9%. It is spread thinly across 38 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations.
Across 100 payments — averaging $23.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$262
- AbbVie$239
- Novartis$193
- Eisai Inc.$171
- Pharmacyclics LLC, An Abbvie Company$170
- Johnson & Johnson$125
- plus $1K from 32 others
What the payments were for
- Food & beverage$1,94484%
- Education$37316%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 6 | $262 |
| AbbVie | 10 | $239 |
| Novartis | 11 | $193 |
| Eisai Inc. | 6 | $171 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $170 |
| Johnson & Johnson(2 entities) | 7 | $125 |
| Exelixis Inc. | 2 | $122 |
| Merck | 5 | $100 |
| Array Biopharma Inc | 4 | $79 |
| AstraZeneca | 4 | $75 |
| Bristol Myers Squibb | 4 | $66 |
| Novo Nordisk | 2 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Pharmaessentia USA Corporation | 2 | $48 |
| Gilead | 2 | $38 |
| Astellas Pharma US Inc | 2 | $38 |
| Genentech USA, Inc. | 2 | $37 |
| Genmab U.S., Inc. | 2 | $36 |
| Pfizer | 2 | $31 |
| CTI Biopharma Corp. | 2 | $28 |
| Mirati Therapeutics, Inc. | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Beigene USA, Inc. | 1 | $24 |
| Blue Earth Diagnostics | 1 | $20 |
| EMD Serono, Inc. | 1 | $19 |
| Rigel Pharmaceuticals, Inc. | 1 | $18 |
| Servier Pharmaceuticals LLC | 1 | $18 |
| Incyte Corporation | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Adaptive Biotechnologies Corporation | 1 | $16 |
| Stemline Therapeutics Inc. | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Spectrum Pharmaceuticals Inc. | 1 | $14 |
| Sobi, Inc | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Dova Pharmaceuticals | 1 | $12 |
| Sanofi | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMBRUVICA$121
How this compares
$2,317 in reported general payments places this provider in the 80th percentile of 58 adult health providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 35 | $519,336 |
| XtandiEnzalutamide | 17 | $261,905 |
| ImbruvicaIbrutinib | 11 | $179,677 |
| BrukinsaZanubrutinib | 12 | $167,431 |
| SprycelDasatinib | 11 | $152,990 |
| Abiraterone Acetate | 31 | $41,165 |
| XareltoRivaroxaban | 14 | $7,844 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $544 |
| Acyclovir | 44 | $361 |
| Anastrozole | 32 | $356 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $315 |
| Prednisone | 39 | $223 |
| Potassium Chloride | 28 | $220 |
| Dexamethasone | 18 | $194 |
| Letrozole | 12 | $190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance | $31 | $519,33635 claims |
| Astellas Pharma US IncXtandi | $38 | $261,90517 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $170 | $179,67711 claims |
| Beigene USA, Inc.Brukinsa | $24 | $167,43112 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $51 | $152,99011 claims |
| Johnson & JohnsonXarelto | $125 | $7,84414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 58 adult health providers in Nebraska.
Other adult health in Lincoln
- Amy KingLincoln$7K
- Heather MosleyLincoln$6K
- Korinne MurcekLincoln$4K
- Stacy SveenLincoln$3K
- Mary BaxterLincoln$3K
- Shirley Mohr-BurtLincoln$2K
- Kelly FieldsLincoln$2K
- Thien KieuLincoln$2K
- Lauren KellyLincoln$1K
- Rhonda OlmstedLincoln$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.